Double blind comparative trial of abana and methyldopa for monotherapy of hypertension in Indian patients.

Publisher Website
Google Scholar
Abstract
Abana is a herbomineral medicinal preparation with a property of down-regulation of beta-adrenergic receptors. A double-blind, parallel group study was conducted in 43 Indian men and women suffering from hypertension to evaluate the antihypertensive effect of Abana and compare it with that of methylodpa (M-DOPA). Twenty-one patients received 800 mg tds of Abana and 22 patients received 250 mg tds of M-DOPA for 4 weeks. Blood pressure and pulse rate were recorded at weekly intervals. Relevant clinical and biochemical investigations were carried out before and after treatment. In patients treated with Abana, there was a significant fall both in systolic B.P. (from 167.+-.3.73 to 145.+-.6.11 mmHg) and in diastolic B.P. (from 110.+-.1.86 to 91.+-.3.04 mmHg) at the end of 4 weeks. Similarly in patients treated with M-DOPA, systolic blood pressure was significantly reduced from 165.+-.4.92 to 146.+-.4.9 mmHg and diastolic blood pressure was reduced from 106.+-.2.74 to 96.+-.2.67 mmHg after 4 weeks. The onset of antihypertensive effect was earlier and there was a higher percentage of responders (80%) in the Abana-treated group. None of the patients had clinically or biochemically significant side-effects. The results of this study suggest that therapy with Abana provide highly effective in hypertensive patients.

This publication has 0 references indexed in Scilit: